Delisting risk
bioAffinity Technologies
Runs a pathology laboratory and sells a sputum-based lung-cancer assessment test.
$4.90
After-hours close+0.03 (+0.62%)
At close$4.87(−3.75%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$31.50 | — | — |
| Aug 2026 | −$2.10 | −$0.64 | +69.5% |
| May 2026 | −$2.40 | −$0.81 | +66.3% |
| Mar 2026 | −$2.70 | −$1.11 | +58.9% |
| Nov 2025 | −$2.70 | −$2.70 | 0.0% |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Apr 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Sep 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | −$31.50 | — | — | $1.9M | — | — |
| Aug 7, 2026 | −$2.10 | −$0.64 | +69.5% | $1.7M | $1.5M | −11.2% |
| May 8, 2026 | −$2.40 | −$0.81 | +66.3% | $1.5M | $1.4M | −8.9% |
| Mar 13, 2026 | −$2.70 | −$1.11 | +58.9% | $1.6M | $1.6M | +2.5% |
| Nov 14, 2025 | −$2.70 | −$2.70 | 0.0% | $1.4M | $1.4M | +2.5% |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | ||||||
| Aug 14, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 31, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 15, 2024 | ||||||
| Apr 1, 2024 | ||||||
| Nov 14, 2023 | ||||||
| Aug 14, 2023 | ||||||
| May 15, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Sep 2, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||